The use of adalimumab for cricoarytenoid arthritis in ankylosing spondylitis--an effective therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 21271584.
- Also identified by DOI 10.1002/lary.21343.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This report describes cartilaginous regeneration in a cricoarytenoid joint affected by spondyloarthropathy using tumor necrosis factor-alpha (TNF-α) blockade, monitored by magnetic resonance (MR) and computed tomography (CT) imaging. This case is interesting for several reasons. It is only the eighth case of destructive ankylosing spondylitis-related cricoarytenoid arthritis published in the English language literature. It describes, for the first time, full recovery of vocal cord mobility following TNF-α blockade. It is also the first case to be published with MR imaging demonstrating regeneration of the cricoarytenoid cartilage following treatment. This case represents a landmark in the treatment of patients presenting with destructive arthritis involving the cricoarytenoid joint.
Medical subject headings
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Arthritis
- Arytenoid Cartilage
- Cricoid Cartilage
- Spondylitis, Ankylosing